Nycomed, a Takeda Company, today announced that Jostein Davidsen has been appointed Head of Emerging Markets in addition to his current role as Area Head of Russia/CIS. He will report to Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International, and CEO of Nycomed. The appointment is effective immediately.
Nycomed’s presence in Emerging Markets was a key driver for Takeda to acquire Nycomed at the end of September 2011. These fast-growing markets are an important lever to achieve Takeda’s sustainable growth aspirations as outlined in the 2011-2013 Mid-Range-Plan. The Emerging Markets Region comprises Russia/CIS, Latin America, Middle East-Turkey-Africa, and South Asia.
“Jostein’s strong track record of leading Russia/CIS over the past 17 years makes him an ideal candidate for this position.” said Frank Morich, EVP, International Operations (Americas/Europe), Takeda Pharmaceuticals International and CEO, Nycomed. “His extensive knowledge of the industry, combined with vision and tenacity, has propelled Russia/CIS to become one of Nycomed’s top revenue contributors.”
Jostein Davidsen has been leading the legacy Nycomed Russia/CIS area since 1994. Since then, the region has grown into the company’s largest market. Today, Nycomed: a Takeda Company is among the top 10 companies in sales in Russia and all of the CIS pharmaceutical markets and has outpaced average market growth more than two times in the last decade. In 2010, Russia/CIS had total sales of €479 million, growing by 31% in local currencies. The company has established itself as a preferred partner for international pharmaceutical companies in Russia/CIS. Nycomed is investing in a pharmaceutical manufacturing facility in Yaroslavl, making it one of the first international companies in Russia to take such a step.
About Nycomed: a Takeda Company
Nycomed is a Takeda company since end of September 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Takeda’s traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed’s position in Europe and the high growth emerging markets. The combined company has a presence in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe.
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.